02nd week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110009271 | EMULSIFIABLE CONCENTRATE COMPOSITION - Disclosed is an emulsifiable concentrate composition characterized by containing not less than 0.5% by weight but not more than 25% by weight of a hydrophobic agrochemically active compound, not less than 5% by weight but not more than 15% by weight of a surfactant, not less than 2% by weight but not more than 60% by weight of an aromatic hydrocarbon solvent, not less than 2% by weight but not more than 60% by weight of γ-butyrolactone, and not less than 12% by weight but not more than 90% by weight of 1,3-dimethyl-2-imidazolidinone. The emulsifiable concentrate composition is also characterized in that the weight ratio of 1,3-dimethyl-2-imidazolidinone to γ-butyrolactone, namely (1,3-dimethyl-2-imidazolidinone):(γ-butyrolactone) is within the range from 1:0.03 to 1:2. | 2011-01-13 |
20110009272 | SUPERABSORBENT COMPOSITION WITH METAL SALICYLATE FOR ODOR CONTROL - The present invention relates to a water-absorbing composition comprising water-absorbing polymer structures and a compound of the structure I | 2011-01-13 |
20110009273 | RE123-BASED OXIDE SUPERCONDUCTOR AND METHOD OF PRODUCTION OF SAME - A method of production of a RE123-based oxide superconductor, said method of production of a RE123-based oxide superconductor characterized by comprising (i) firing a pulse laser at an oxide-based target including RE, Ba, and Cu satisfying the following formulas (1) and (2) to form a plume and (ii) holding a substrate in that plume to form an RE123-based oxide superconducting film: | 2011-01-13 |
20110009274 | MAGNETIC VACUUM SYSTEMS AND DEVICES FOR USE WITH SUPERCONDUCTING-BASED COMPUTING SYSTEMS - Magnetic shields and magnetic shielding systems are described. The excessive spatial demands of known mu-metal/cryoperm and superconducting shielding systems are reduced by a new multi-piece shield construction approach. A complete magnetic shielding system for use with superconducting-based computing systems, such as superconducting quantum computing systems, is also described. This complete system may include mu-metal/cryoperm shields and superconducting shields using either compensatory magnetic fields, expulsion by temperature gradients, or a combination of the two. | 2011-01-13 |
20110009275 | Methods of amplifying and sequencing nucleic acids - An apparatus and method for performing rapid DNA sequencing, such as genomic sequencing, is provided herein. The method includes the steps of preparing a sample DNA for genomic sequencing, amplifying the prepared DNA in a representative manner, and performing multiple sequencing reaction on the amplified DNA with only one primer hybridization step. | 2011-01-13 |
20110009276 | Method for Sequencing a Polynucleotide Template - The invention provides methods for pairwise sequencing of a double-stranded polynucleotide template, which methods result in the sequential determination of nucleotide sequences in two distinct and separate regions of the polynucleotide template. | 2011-01-13 |
20110009277 | METHOD FOR METHYLATION ANALYSIS - Aspects of the invention relate to composition and methods for the providing of DNA for methylation analysis that is in particular suitable to be applied in reference laboratories. Further 5 aspects of the invention relate to composition and methods for the highly specific and sensitive methylation analysis of the Septin 9 gene also in particular suitable to be applied in reference laboratories. | 2011-01-13 |
20110009278 | NUCLEIC ACID SEQUENCING SYSTEM AND METHOD - A technique for sequencing nucleic acids in an automated or semi-automated manner is disclosed. Sample arrays of a multitude of nucleic acid sites are processed in multiple cycles to add nucleotides to the material to be sequenced, detect the nucleotides added to sites, and to de-block the added nucleotides of blocking agents and tags used to identify the last added nucleotide. Multiple parameters of the system are monitored to enable diagnosis and correction of problems as they occur during sequencing of the samples. Quality control routines are run during sequencing to determine quality of samples, and quality of the data collected. | 2011-01-13 |
20110009279 | Methods of Diagnosing Non-Alcoholic Steatohepatitis (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods. | 2011-01-13 |
20110009280 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 2011-01-13 |
20110009281 | METHODS FOR CREATING AND IDENTIFYING FUNCTIONAL RNA INTERFERENCE ELEMENTS - The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules. In still other aspects, the invention provides methods for identifying a polynucleotide from a plurality of candidate target polynucleotides that is specifically targeted by an RNAi trigger molecule. In other aspects, the invention provides epi-allelic series of hypomorphic RNAi trigger molecules specific for any gene of interest, where the series of RNAi trigger molecules have a variety of uses including analysis of gene function and drug target development. | 2011-01-13 |
20110009282 | HIGH THROUGHPUT SCREENING METHOD AND APPARATUS FOR ANALYSING INTERACTIONS BETWEEN SURFACES WITH DIFFERENT TOPOGRAPHY AND THE ENVIRONMENT - The invention is directed to a high throughput screening method for analyzing and interaction between a surface of a material and an environment. The screening method of the invention comprises: providing a micro-array comprising said material and having a multitude of units at least part of which have different topography; contacting at least part of said multitude of units with said environment; and screening said micro-array for an interaction between one or more of said units and said environment. | 2011-01-13 |
20110009283 | IDENTIFICATION OF TOXIN LIGANDS - The disclosure relates to a method and system of screening for ligands which specifically bind to receptors. The method comprises expressing at least one receptor. The at least one receptor is contacted with a sample comprising at least one ligand. Whether the ligand selectively binds to the receptor is determined. | 2011-01-13 |
20110009284 | GENE RELATING TO ESTIMATION OF POSTOPERATIVE PROGNOSIS FOR BREAST CANCER - It is intended to provide a system of predicting the postoperative prognosis in a patient with breast cancer from the viewpoint of gene expression based on the data obtained by genome-wide and comprehensive analysis on gene expression in breast cancer. Expression of human genes is comprehensively analyzed by using a DNA microarray and gene expression functions in various breast cancer conditions are compared, thereby establishing a system of predicting the postoperative prognosis of breast cancer. | 2011-01-13 |
20110009285 | METHOD OF DIAGNOSING A PROGRESSIVE DISEASE - A method of determining the risk of progressive renal disease in a patient, by measuring a parameter related to a marker selected from the group of IL1RN, ISG15, LIFR, C6, IL32 and any combination thereof, in a sample of said patient. | 2011-01-13 |
20110009286 | MOLECULAR IN VITRO DIAGNOSIS OF BREAST CANCER - The invention relates to the use of a multiplicity of polynucleotide probe sets, the multiplicity of polynucleotide probe sets consisting in a combination of pools of polynucleotide probe sets, each polynucleotide probe set containing at least one polynucleotide probe chosen among a library of nucleic acid sequences, the polynucleotide probes involved in the combination of pools of polynucleotide probe sets of the multiplicity of polynucleotide probe sets being such that each polynucleotide probe specifically hybridizes with one gene, and/or at least one of its variants when present, for determining the variation of expression at least 12 genes, and their variants when present, in order to diagnose the benign or malignant state of a breast tumor. | 2011-01-13 |
20110009287 | PURIFICATION OF MONOCLONAL ANTIBODIES - Methods and compositions for efficiently purifying monoclonal antibodies and identifying pairs of antibodies compatible in sandwich immunoassays are provided. | 2011-01-13 |
20110009288 | METHODS AND REAGENTS FOR THE EARLY DETECTION OF MELANOMA - An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value. | 2011-01-13 |
20110009289 | METHODS OF USING AN ARRAY OF POOLED PROBES IN GENETIC ANALYSIS - The invention provides arrays of polynucleotide probes having at least one pooled position. A typical array comprises a support having at least three discrete regions. A first region bears a pool of polynucleotide probes comprising first and second probes. A second region bears the first probe without the second probe and a third region bears the second probe without the first probe. A target nucleic acid having segments complementary to both the first and second probes shows stronger normalized binding to the first region than to the aggregate of binding to the second and third regions due to cooperative binding of pooled probes in the first region. The invention provides methods of using such arrays for e.g., linkage analysis, sequence analysis, and expression monitoring. | 2011-01-13 |
20110009290 | Methods for Identifying One or More Bioactive Genes - The present invention relates to methods for identifying one or more bioactive genes, comprising: (a) introducing an expressible genomic DNA library derived from a first organism or a group of first organisms into a second organism, wherein said genomic DNA library is comprised in a copy inducible vector in said second organism; (b) growing said multitude of clones of said second organism at a low copy number of said vector and at high copy number of said vector; (c) identifying one or more clones of said second organism wherein said identification comprises identifying altered growth characteristic; and (d) identifying in the one or more clones of said second organism identified in step (c) one or more genes of said first organism or said group of first organisms providing the altered growth characteristic, thereby identifying the one or more bioactive genes. | 2011-01-13 |
20110009291 | METHODS AND COMPOSITIONS FOR INCREASING MEMBRANE PERMEABILITY - Methods and compositions for increasing membrane permeability are provided. One aspect provides protein resulting from a fusion between a membrane-active peptide and second peptide. Nucleic acids and vectors encoding the pore forming fusion proteins are also provided. | 2011-01-13 |
20110009292 | ATTACHMENT OF MOLECULES TO SURFACES - The present invention relates to methods, reagents, and substrates that can be used for, for example, immobilizing biomolecules, such as nucleic acids and proteins. In an embodiment, the present invention relates to surfaces coated with a polymer according to the present invention. In an embodiment, the present invention relates to methods for thermochemically and/or photochemically attaching molecules to a surface at a high density. | 2011-01-13 |
20110009293 | Nonseparation Assay Methods - Assay methods are disclosed involving specific binding reactions which are simplified compared to known methods. A compound capable of producing chemiluminescence is immobilized on a solid support as is a member of a specific binding pair for capturing an analyte from a sample. An activator compound that activates the chemiluminescent compound and is conjugated to a specific binding pair member is added in excess along with the sample to the solid support. Addition of a trigger solution causes a chemiluminescent reaction at the sites where the activator conjugate has been specifically bound. The assay methods are termed non-separation assays because they do not require removal or separation of excess detection label (activator conjugate) prior to the detection step. The methods are applicable to various types of assays including immunoassays, receptor-ligand assays and nucleic acid hybridization assays. | 2011-01-13 |
20110009294 | Methods for Genotyping Selected Polymorphism - Methods for genotyping polymorphisms using a locus specific primer that is complementary to a region near a selected polymorphism are described. Methods for synthesizing pools of locus specific primers that incorporate some degenerate positions are also disclosed. A plurality of different sequence capture probes are synthesized simultaneously using degenerate oligonucleotide synthesis. The sequence of the locus specific regions of the capture probes are related in that they have some bases that are identical in each sequence in the plurality of sequences and positions that vary from one locus specific region to another. The sequences are selected based on proximity to a polymorphism of interest and because they conform to a similar sequence pattern. | 2011-01-13 |
20110009295 | SYSTEM, HEATING BLOCK AND METHOD - The present invention provides a system, comprising at least one reactor array, comprising at least two reactor vessels ( | 2011-01-13 |
20110009296 | NUCLEIC ACID SEQUENCING SYSTEM AND METHOD - A technique for sequencing nucleic acids in an automated or semi-automated manner is disclosed. Sample arrays of a multitude of nucleic acid sites are processed in multiple cycles to add nucleotides to the material to be sequenced, detect the nucleotides added to sites, and to de-block the added nucleotides of blocking agents and tags used to identify the last added nucleotide. Multiple parameters of the system are monitored to enable diagnosis and correction of problems as they occur during sequencing of the samples. Quality control routines are run during sequencing to determine quality of samples, and quality of the data collected. | 2011-01-13 |
20110009297 | Consumable elements for use with fluid processing and detection systems - One embodiment describes an automated and flexible system to analyze probe arrays. It comprises a plurality of arrays mounted on pegs that are moved by an instrument handling robot to liquid reaction stations. | 2011-01-13 |
20110009298 | Ultra High Viscosity Pill and Methods for Use with An Oil-Based Drilling System - A fluid pressure transmission pill (FPTP) having an ultra-high viscosity for use in association with hydrocarbon drilling and exploration operations, particularly, managed pressure drilling (MPD) operations, is described. The ultra-high viscosity pill is a weighted pill composition that includes a hydrocarbon fluid, a thixotropic viscosifying agent, one or more activators, an emulsifier/wetting agent, a fluid loss control additive, and a weighting material. In accordance with selected aspects of the described fluid pressure transmission pill, the ratio of the amount of the thixotropic viscosifying agent to the activator is a ratio of about 7:1, and the weighting material is a barium-containing solid-phase material. Also described are methods of use of such FPTP products in subterranean operations, such as well killing operations during managed pressure drilling. | 2011-01-13 |
20110009299 | EMULSION STABILIZING AGENTS FOR DRILLING AND COMPLETION FLUIDS - Of the many methods presented herein, one method comprises: providing a stabilized emulsion composition formed by combining components that comprise: an oleaginous fluid, a fluid that is at least partially immiscible with the oleaginous fluid, and an emulsion stabilizing agent, wherein the emulsion stabilizing agent comprises a first ionic compound soluble in the oleaginous fluid or the fluid that is at least partially immiscible with the oleaginous fluid, and a second ionic compound with a charge of opposite sign of the first ionic compound and that is at least partially soluble in the opposite fluid as the first ionic compound, and placing the stabilized emulsion composition in a subterranean formation as part of a subterranean application. | 2011-01-13 |
20110009300 | SYNTHESIS OF BIOLUBRICANT ESTERS FROM UNSATURATED FATTY ACID DERIVATIVES - The present invention is generally directed to diester-based lubricant compositions comprising one or more isomeric mixtures of diester species. The present invention is also directed to methods of making these and other similar lubricant compositions. In some embodiments, the methods for making such diester-based lubricants utilize a biomass precursor material from which mono-unsaturated free lipid species can be provided or otherwise generated, wherein such mono-unsaturated free lipid species arc converted to isomeric diol species en route to the synthesis of diester species for use as/in the diester-based lubricant compositions. | 2011-01-13 |
20110009301 | Universal Synthetic Golf Club Cleaner and Protectant, Method and Product-by-Process to Clean, Protect Golf Club Faces and Rejuvenate Golf Clubs Grips - The club cleaner, conditioner and protectant comprises alpha-olefins, low-odor aromatic solvents; and at least one base oil selected from the base oil group consisting of Hydrolsomerized high base oils and HT Sever Hydro-cracked Base oils; as well as other (optional) ingredients. Also disclosed is a method for producing this product and related product-by-process. This product uses a formulated cleaning mixture to clean and restore the face of the club while rejuvenating the grips. The invention when sprayed on the clubface removes foreign materials and when wiped dry protects the face of the clubs from harsh stains, caused by soils, grass and chemicals related to fertilizers. In experimental testing, the invention increases drive distances by reducing sidespin and increasing backspin. The club is left with a factory-like finish making it easy to wipe clean of soiling. The invention when applied to the grips restores the surface to the new feel. | 2011-01-13 |
20110009302 | Mild, Structured, Multi-Phase Personal Cleansing Compositions Comprising Density Modifiers - A mild, multi-phase cleansing composition is described that includes a cleansing phase including a structured surfactant component has a first density; a benefit phase includes an emulsion, the benefit phase has a second density and a density modifier; wherein the first density differs from the second density by less than 0.15 g/cm | 2011-01-13 |
20110009303 | AUTOMATIC DISHWASHING COMPOSITION CONTAINING A SULFONATED COPOLYMER - An ADW composition comprising a builder and a water-soluble copolymer which comprises: (a) from about 30 to 60 mol % of the copolymer having a structural unit originating from a monoethylenic unsaturated dicarboxylic acid (or dicarboxylate) monomer having 4 to 6 carbon atoms or its anhydride at; (b) from about 30 to 60 mol % of the copolymer having a structural unit originating from a monoethylenic unsaturated monocarboxylic acid (or monocarboxylate) monomer having 3 to 8 carbon atoms; and (c) from about 5 to 15 mol % of the polymer having a structural unit originating from a monoethylenic unsaturated monomer having a sulfonic (or sulfonate) group; wherein the water-soluble copolymer has a weight average molecular weight of from about 1,000 to about 50,000 wherein the copolymer is polymerized with hydrogen peroxide. | 2011-01-13 |
20110009304 | COMPOSITIONS CONTAINING BLEACH CO-PARTICLES - Compositions that contain a co-particle, a bleach catalyst, and optionally, a detergent adjunct material are disclosed. The disclosed co-particles contain a binder, a hydrogen peroxide source, such as sodium percarbonate or the like, and a bleach activator such as TAED. Methods of making and using these compositions are also disclosed. | 2011-01-13 |
20110009305 | Layered Particles and Compositions Comprising Same - Layered particles that contain a source of hydrogen peroxide, a binder material, and a bleach activator and a method of improving the stability of a source of hydrogen peroxide. The layered particles can be incorporated into granular detergents. | 2011-01-13 |
20110009306 | COMPOSITIONS CONTAINING BENEFIT AGENT DELIVERY PARTICLES - The present disclosure relates to benefit agent delivery particles containing at least one benefit agent and at least one cellulosic polymer. The disclosure further relates to fabric care compositions containing benefit agent delivery particles and processes for making and using such compositions. The disclosure further relates to methods of imparting a benefit delivery capability to a fabric care composition. | 2011-01-13 |
20110009307 | Laundry Detergent Composition Comprising Low Level of Sulphate - A laundry detersive composition. The composition has (i) from about 1 wt % to about 60 wt % detergent surfactant; (ii) from about 0 wt % to about 10 wt % zeolite builder; (iii) from about 0 wt % to about 10 wt % phosphate builder; (iv) from about 0 wt % to about 10 wt % inorganic sulphate salt and (v) balance detergent ingredients. | 2011-01-13 |
20110009308 | Subtilase Variants Having Altered Immunogenicity - The present invention relates to subtilase subtilases with an altered immunogenicity, particularly subtilases with a reduced allergenicity. Furthermore, the invention relates to expression of said subtilase variants and subtilases and to their use, such as in detergents and oral care products. | 2011-01-13 |
20110009309 | Hard Surface Cleaning Composition - The present invention relates to a hard surface cleaning composition comprising a polybetaine polymer, wherein said polybetaine polymer comprises a zwitterionic unit A or a mixture thereof, wherein said unit A comprises a betaine group or a mixture thereof and wherein said betaine group of said unit A is a sulphobetaine group or a mixture thereof, and a vinylpyrrolidone homopolymer or copolymer, wherein said polybetaine polymer and said vinylpyrrolidone homopolymer or copolymer are present in said composition at a weight ratio of polybetaine polymer to vinylpyrrolidone homopolymer or copolymer of at utmost 1.5:1. | 2011-01-13 |
20110009310 | Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation - Soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in chick and mouse and thereby inhibits human tumor growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble non glycosylated CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumors using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues are presented. | 2011-01-13 |
20110009311 | PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING ALPHA3 BETA1 INTEGRINS - The present invention relates to a peptide comprising the sequence R | 2011-01-13 |
20110009312 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2011-01-13 |
20110009313 | POLYETHYLENE GLYCOLATED LACTOFERRIN COMPLEX AND METHOD OF PRODUCING THE SAME - A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive. | 2011-01-13 |
20110009314 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 2011-01-13 |
20110009315 | LONG-ACTING TRANSIENT POLYMER CONJUGATES OF EXENDIN - Long-acting polymer exendin-4 or exendin agonist derivatives of the formula Pol-L-E are provided wherein Pol is a polymer, L is a releasing linker undergoing slow autohydrolysis and E is an exendin or exendin agonist. These exendin or exendin agonists are slowly released from Pol-L upon administration to a living organism. The derivatives are useful e.g. for the treatment of diabetes mellitus. | 2011-01-13 |
20110009316 | PROTEOLYSIS RESISTANT ACTIVE VEGF - The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds. | 2011-01-13 |
20110009317 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 2011-01-13 |
20110009318 | Transdermal Compositions and Methods for Treatment of Fibromyalgia and Chronic Fatigue Syndrome - Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones. | 2011-01-13 |
20110009319 | CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING - Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b. | 2011-01-13 |
20110009320 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 2011-01-13 |
20110009321 | NASAL CALCITONIN FORMULATIONS CONTAINING CHLOROBUTANOL - An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia. | 2011-01-13 |
20110009322 | USE OF BRADYKININ AND RELATED B2R AGONISTS TO TREAT OCULAR HYPERTENSION AND GLAUCOMA - The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B | 2011-01-13 |
20110009323 | NON-IMMUNOGLOBULIN ANTIGEN BINDING SCAFFOLDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide or nucleotide non-immunoglobulin antigen binding scaffold compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2011-01-13 |
20110009324 | Stable Therapeutic Proteins - The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are either free or bound to the substrates thereof and act against the therapeutic protein(s) present. | 2011-01-13 |
20110009325 | CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS - Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof: | 2011-01-13 |
20110009326 | METHODS OR USE OF LAMIN B1 NUCLEAR ANTIGEN, FRAGMENTS AND COMPOSITIONS THEREOF, FOR INHIBITING OR REDUCING A THROMBOTIC EVENT - A method for preventing a thrombotic event in a patient susceptible to such an event, which comprises the step of administering an effective amount of a lamin 131 nuclear (LB1) antigen to said patient is provided along with an anti-thrombotic composition which comprises an effective amount of a lamin 131 nuclear (LB1) antigen and a pharmaceutically acceptable carrier. | 2011-01-13 |
20110009327 | BIOACTIVE NANOCOMPOSITE MATERIAL - The present invention relates to a porous inorganic/organic hybrid nanoscale composite comprising an enzymatically biodegradable organic polymer and a sol-gel derived silica network, its production and use as a macroporous scaffold in tissue engineering. | 2011-01-13 |
20110009328 | Polypeptide Derivatives of Parathyroid Hormone (PTH) - Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds. | 2011-01-13 |
20110009329 | METHOD FOR TREATING NEURODEGENERATIVE DISEASES - A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide | 2011-01-13 |
20110009330 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 2011-01-13 |
20110009331 | PROTEIN KINASE C PEPTIDES FOR USE IN WITHDRAWAL - A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for εPKC or γPKC and instructions for use. | 2011-01-13 |
20110009332 | Therapeutic Treatment Of Wounds - The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin. | 2011-01-13 |
20110009333 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION - Disorders of the skin or mucous membranes which are linked to migration of Langerhans cells are treated by the administration of an effective amount of at least one retinoid, optionally in combination with a PKC inhibitor. | 2011-01-13 |
20110009334 | SYSTEM AND METHOD FOR INHIBITING CELLULAR PROLIFERATION WITH TACHYKININS - Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin. | 2011-01-13 |
20110009335 | Anticancer Treatments - The present invention relates to combinations of aplidine with another anticancer drug selected from sorafenib, temsirolimus, and sunitinib, and the use of these combinations in the treatment of cancer. | 2011-01-13 |
20110009336 | Treatment of Cancers with Immunostimulatory HIV TAT Derivative Polypeptides - Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide. | 2011-01-13 |
20110009337 | Q3 SPARC DELETION MUTANT AND USES THEREOF - The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies. | 2011-01-13 |
20110009338 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 2011-01-13 |
20110009339 | METHOD OF TREATING BLURRED VISION AND OTHER CONDITIONS OF THE EYE WITH CYCLOSPORIN COMPOSITIONS - Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual. | 2011-01-13 |
20110009340 | COMBINATION OF AN IRON CHELATOR AND AN IMMUNOSUPPRESSANT AND USE THEREOF - The invention relates to a combination comprising an iron chelator and an immunosuppressant, to the use of such combination for the improvement of immunosuppression, e.g. in hematopoietic stem cell transplantation. | 2011-01-13 |
20110009341 | N-Alkylated Cyclic Peptide Melanocortin Agonists - A melanocortin-4 receptor agonist cyclic peptide of the formula | 2011-01-13 |
20110009342 | USES OF PDCD5 POLYPEPTIDE FOR TUMOR CHEMOTHERAPY AND ORGAN PROTECTION - The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof. | 2011-01-13 |
20110009343 | MODULATORS OF AMYLOID AGGREGATION - Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed. | 2011-01-13 |
20110009344 | Control of radiation injury - The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals. | 2011-01-13 |
20110009345 | Food ingredient comprising functional peptide - With efficient extracting of peptide from coffee bean, and by providing food ingredient in which small quantity of peptide is uniformly dispersed by harmless means or dispersing means, the peptide is easily orally ingested. That is, so much material and long time is required for extracting. And, quantity of novel ingredient of peptide obtainable by the extracting is very small, so it is difficult to use the ingredient as it is for material of medicine or food. So, it is inevitable to disperse uniformly in harmless extender. And, for example, solubility of vegetable peptide is generally much influenced by pH or concentration of salt (ion intensity), so particularly in acidic zone, solubility of it deteriorates and it deposits or coheres, ingestion by oral administration of it mixed with food is not always easy, so it is required to disperse the peptide uniformly in harmless means or dispersing means. | 2011-01-13 |
20110009346 | Methods and compositions for increasing the anaerobic working capacity in tissues - Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 2011-01-13 |
20110009347 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES - The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein. | 2011-01-13 |
20110009348 | CARBOHYDRATE GEL - The present invention generally relates to the field of nutrition, in particular performance nutrition. In particular, the present invention relates to a novel carbohydrate gel comprising glucose and fructose in a ratio in the range of 3:1 to 1:1. The carbohydrate gel of the present invention can be used to treat or prevent problems with the gastrointestinal tract while allowing for an enhanced blood sugar maintenance and/or an increased exogenous carbohydrate oxidation. | 2011-01-13 |
20110009349 | METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT - One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject. | 2011-01-13 |
20110009350 | Oil-in-Water Formulation of Avermectins - Oil-in-water emulsion formulations (EW) of avermectins based on esters of fatty acids as solvent and the use of such formulations for the control of crop pests. | 2011-01-13 |
20110009351 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS - The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function in a multiwell format when cells are exposed to libraries of compounds. Although such functional assays are useful, they do not directly test the ability of a compound to correct defective trafficking of the protein. To address this a novel corrector screening assay for CF has been developed in which the appearance of the mutant protein at the cell surface is measured as the assay output. This assay was used to screen more than 3100 compounds. This novel screening approach to protein trafficking diseases is robust and general, and may enable the selection of molecules that can be translated rapidly to a clinical setting. | 2011-01-13 |
20110009352 | RESTORATIVE AGENT FOR ANTIBACTERIAL PEPTIDE PRODUCTION ABILITY - There is provided a medicament capable of enhancing the antimicrobial peptide production ability. The medicament contains, as an active ingredient, a compound which is glycyrrhizin or a pharmaceutically acceptable salt thereof and capable of inhibiting the production of at least one of interleukin-10 (IL-10) and chemokine CCL2. The antimicrobial peptide is preferably defensin or cathelicidin. | 2011-01-13 |
20110009353 | TARGETING CDK4 AND CDK6 IN CANCER THERAPY - The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies. | 2011-01-13 |
20110009354 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE - The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5′-deoxy-5′-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5′-deoxy-5′-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally. | 2011-01-13 |
20110009355 | Azapeptide Derivatives - This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir. | 2011-01-13 |
20110009356 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS - Novel cyclic phosphoramidate prodrugs of drugs of formula I | 2011-01-13 |
20110009357 | LIPID COMPOSITION FOR IMPROVING BRAIN FUNCTION - The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g α-linolenic acid per 100 g fatty acids of the lipid fraction. | 2011-01-13 |
20110009358 | AGENT FOR SUPPRESSING GLUCOSE LEVEL INCREASE, AGENT FOR SUPPRESSING BODY FAT ACCUMULATION AND FOOD COMPOUND - A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneous with consuming the carbohydrate, and wherein the reducer reduces the individual's body fat accumulation caused by consuming the carbohydrate. The reducer of body fat accumulation includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, accumulation of body fat resulting from ingesting the carbohydrate is reduced. | 2011-01-13 |
20110009359 | USE OF NON-DIGESTIBLE CARBOHYDRATES FOR IMPROVING INTESTINAL MICROBIOTA - A composition comprising at least two non-digestible carbohydrates for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition. | 2011-01-13 |
20110009360 | Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis - The present invention embraces nutraceutical compositions containing isolated | 2011-01-13 |
20110009361 | DESIGN AND SELECTION OF MEDICAMENTS THAT MODULATE THE FUNCTION AND ACTIVITY OF INTERLEUKIN 13 - The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL-13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative, and the use of said IL-13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated. | 2011-01-13 |
20110009362 | SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided. | 2011-01-13 |
20110009363 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) - This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress. | 2011-01-13 |
20110009364 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to compounds of formula (I): | 2011-01-13 |
20110009365 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - This disclosure relates to compounds of formula (I): | 2011-01-13 |
20110009366 | BICYCLIC PYRIMIDINONES AND USES THEREOF - The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided. | 2011-01-13 |
20110009367 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS - The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction. | 2011-01-13 |
20110009368 | SOLID FORMS OF TENOFOVIR DISOPROXIL - The Present Invention Provides Tenofovir Disoproxil Succinate, Tenofovir Disoproxil L-Tartrate, Tenofovir Disoproxil oxalate, Tenofovir disoproxil saccharate, Tenofovir disoproxil citrate, Tenofovir disoproxil salicylate and various solid forms thereof, methods for the preparation thereof and their use in pharmaceutical applications, in particular in anti-HIV medicaments. The forms of Tenofovir disoproxil can be used in combination with other anti-HIV medicaments such as Efavirenz and Emtricitabine. | 2011-01-13 |
20110009369 | ANTI-INFLUENZA COMPOUNDS - The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds of the invention can also be used for the treatment or prophylaxis of a disease caused by | 2011-01-13 |
20110009370 | METHOD TO ENHANCE TISSUE REGENERATION - The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect. | 2011-01-13 |